A detailed history of Comerica Bank transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Comerica Bank holds 94 shares of EDIT stock, worth $256. This represents 0.0% of its overall portfolio holdings.

Number of Shares
94
Previous 1,130 91.68%
Holding current value
$256
Previous $1,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 14, 2025

SELL
$1.14 - $3.2 $1,181 - $3,315
-1,036 Reduced 91.68%
94 $0
Q4 2024

Feb 14, 2025

BUY
$1.2 - $3.76 $1,159 - $3,632
966 Added 589.02%
1,130 $1,000
Q3 2024

Nov 14, 2024

BUY
$3.39 - $5.96 $237 - $417
70 Added 74.47%
164 $0
Q1 2024

May 15, 2024

SELL
$7.03 - $11.07 $4,956 - $7,804
-705 Reduced 88.24%
94 $0
Q4 2023

Feb 14, 2024

SELL
$6.25 - $11.11 $94,393 - $167,794
-15,103 Reduced 94.98%
799 $8,000
Q3 2023

Nov 21, 2023

BUY
$6.92 - $9.31 $110,041 - $148,047
15,902 New
15,902 $124,000

Others Institutions Holding EDIT

About Editas Medicine, Inc.


  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $188M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.